Regen BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2015 - 2019
Net Income	-0.87	1.16	2.44	-6.77	3.41	Upgrade
Other Amortization	0.03	0	0.07	0.05	0.61	Upgrade
Loss (Gain) From Sale of Investments	0.2	-	-0.03	1.16	-	Upgrade
Stock-Based Compensation	0.15	0.25	0.05	0	0	Upgrade
Other Operating Activities	-	0.35	0	-1.87	-	Upgrade
Change in Accounts Receivable	-0.09	0.25	-0.04	-0.11	-0.03	Upgrade
Change in Accounts Payable	-0	0	-0.06	-0.02	0.02	Upgrade
Change in Unearned Revenue	-0.14	-0.11	-0.13	1.84	-	Upgrade
Change in Other Net Operating Assets	0.02	-2.07	-2.91	4.59	-3.99	Upgrade
Operating Cash Flow	-0.69	-0.17	-0.61	-1.13	0.02	Upgrade
Investment in Securities	-	-	0.03	0.5	-	Upgrade
Investing Cash Flow	-	-	0.03	0.5	-	Upgrade
Short-Term Debt Issued	0.02	0.24	0	1.36	-	Upgrade
Total Debt Issued	0.02	0.24	0	1.36	-	Upgrade
Short-Term Debt Repaid	-	-	-	-	-0.03	Upgrade
Long-Term Debt Repaid	-0.01	-	-0.09	-	-	Upgrade
Total Debt Repaid	-0.01	-	-0.09	-	-0.03	Upgrade
Net Debt Issued (Repaid)	0.01	0.24	-0.09	1.36	-0.03	Upgrade
Issuance of Common Stock	0.56	-	-	-	-	Upgrade
Financing Cash Flow	0.57	0.24	-0.09	1.36	-0.03	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-	Upgrade
Net Cash Flow	-0.12	0.07	-0.68	0.73	-0.01	Upgrade
Cash Interest Paid	0.02	-	0.03	-	-	Upgrade
Levered Free Cash Flow	-0.41	-2.56	-4.04	5.79	-4.15	Upgrade
Unlevered Free Cash Flow	-0.38	-2.52	-3.98	5.97	-4.17	Upgrade
Change in Net Working Capital	0.27	2.34	3.81	-6.1	4.04	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.